The document discusses pharmacoeconomics and pharmacoepidemiology. It defines pharmacoeconomics as the scientific discipline concerned with the cost and value of drugs, often with the goal of optimizing health care resource allocation. Pharmacoepidemiology is defined as the study of medication use and effects in large populations, applying epidemiological knowledge and methods. The document outlines the objectives, basic equations, types of economic analyses including cost-minimization, cost-effectiveness, cost-benefit, and cost-utility analyses. It also discusses the importance of economic evaluations in clinical decision making and resource allocation.
Safety pharmacology is a branch of pharmacology with its aim to predict the potential clinical risk profile of new chemical entities (NCEs).
It has the ability to predict the potential off-target drug effects on major organ systems which are associated with exposure in the therapeutic range and above.
As an essential part of the spectrum of drug discovery and development, safety pharmacology studies are generally conducted to determine the relative drug effect on main organs, including respiratory system, central nervous system, and cardiovascular system.Safety pharmacology is an essential part of the drug development process that aims to identify and predict adverse effects prior to clinical trials.
SP studies are described in the international conference on harmonization (ICH) S7A and S7B Guidelines.
Guidelines of ADR reporting are mentioned. Where to report? How to report? Whom to report? These are the major part of the ppt. Normal people can understand about the drug safety process.
Safety pharmacology is a branch of pharmacology with its aim to predict the potential clinical risk profile of new chemical entities (NCEs).
It has the ability to predict the potential off-target drug effects on major organ systems which are associated with exposure in the therapeutic range and above.
As an essential part of the spectrum of drug discovery and development, safety pharmacology studies are generally conducted to determine the relative drug effect on main organs, including respiratory system, central nervous system, and cardiovascular system.Safety pharmacology is an essential part of the drug development process that aims to identify and predict adverse effects prior to clinical trials.
SP studies are described in the international conference on harmonization (ICH) S7A and S7B Guidelines.
Guidelines of ADR reporting are mentioned. Where to report? How to report? Whom to report? These are the major part of the ppt. Normal people can understand about the drug safety process.
A brief introduction about Pharmacology of free radicals, generation of free radicals, Antioxidants, Free radicals causing disorders such as cancer diabetes, neuro degenerative disorders such as Parkisonism's Disease
A brief introduction about Pharmacology of free radicals, generation of free radicals, Antioxidants, Free radicals causing disorders such as cancer diabetes, neuro degenerative disorders such as Parkisonism's Disease
Pharmacoeconomics is essential to reduce burden for patients in the terms of cost and improve the therapeutic effectiveness by selecting alternative treatments. Physician and pharmacist plays an important role in selecting drugs and treatment alternatives. So, proper selection helps to minimize the cost of therapy in patients. Research studies on pharmacoeconomics helps to know the burden of patients paying for their illness.
> Why HEOR?
> Costs, Consequences and Perspectives
> Key Stakeholders in HEOR
> What is Health Economics and Pharmaco-economic Research?
> Economic Evaluations
> Incremental Cost Effectiveness Ratio (ICER)
> Concept of HRQoL
> Comparative Effectiveness Research (CER)
> Pragmatic Clinical Trials
> Observational Studies
> Systematic Reviews and Meta-Analysis
> Application of CER
> Health Technology Assessment (HTA)
> Real World Evidence (RWE)
> Patient Reported Outcomes (PROs)
> Patient Focused Drug Development (PFDD)
> Application of Health Economic Evaluations
> Challenges and Barriers
MedicReS Winter School 2017 Vienna - Importance of Selection of Outcomes - Ma...MedicReS
Importance of Selection of Outcomes and Covariates in Comparative Effectiveness of Cancer ...
International Conference Good Biostatistical and Publication Practice in Cancer Research with “Real Work Data”
February 13-14th, Vienna
Mariana Chavez Mac GregorMD, MSc.
Assistant Professor, Health Services Research Department
Breast Medical Oncology Department
Outcomes, health economics and pharmacoeconomicsDureshahwar khan
Pharmacoeconomics can be regarded as a branch of health economics which deals with identifying, measuring, and comparing the costs and consequences of pharmaceutical products and services. Some of the concepts involved in pharmacoeconomic analysis include cost minimization, cost effectiveness, cost benefit, and cost utility analysis.
Similar to Pharmacoeconomics & pharmacoepidemioology (20)
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
4. Pharmacoeconomics is a scientific discipline concerned
with the cost and value of drugs, often with the goal of
optimizing the allocation of health care resources.
5. Definition
“The field of study that evaluates the behaviour of
individuals, firms, and markets relevant to the use of
pharmaceutical products, services, and programs, and
which frequently focuses on the costs (inputs) and
consequences (Outcomes) of that use”
-ISPOR
6. Need And Scope
• Healthcare in India - easy availability and
affordability for the patient
• Responsibility of the caregivers
– maximize the beneficial outcomes
– minimize the financial burden
– increase humanistic outcome goals
7. Need And Scope
• To find the optimal therapy at the lowest price.
• In Industry- To decide among specific research and
development alternatives.
• In Government- To determine program benefits and prices
paid.
• In Private Sector- To design insurance benefit coverage
9. Basic pharmacoeconomic equation
– Left hand side of equation - cost analysis (or a
partial economic analysis)
– Right hand side of equation -clinical or health
outcome study
COSTS(₹) OUTCOMESRX
11. The Pharmaconomic Data
– Evaluation Of Pharmacoeconomic Data Along Side Clinical
Trial
– Naturalistic Pharmacoeconomic Study
– Economic Modelling On The Basis Of Prospectively
Collected Clinical Trial
12. Economic value of a new medicine
= +
COMPARATOR
VALUE
DIFFERENTIAL
VALUE
( savings , clinical
benefits , survival
/Quality of Life
benefits , value in
use )
ECONOMIC
VALUE
13. Evaluations from a
pharmacoeconomic perspective
COSTS(₹) OUTCOMESRX
Evaluation of
cost of
treatment
Evaluation of
health outcome
after treatment
14. Costs From A Pharmacoeconomic
Evaluation Perspective :
• Direct Medical costs
• Direct Non Medical cost
• Indirect cost
• Intangible costs
15. Examples of type of costs
Direct Medical
cost
Medications ( monitoring , administration)
Diagnostic tests
Clinic visits
Nursing services
Ambulance services
Emergency department visits
Hospitalizations
Direct Non
Medical cost
Travel costs to receive health care (bus, gas, taxi)
Nonmedical assistance related to condition (e.g.,
Meals-on-Wheels, homemaking services)
Hotel stays for patient or family for out-of-town
care
16. Examples of type of costs
Indirect cost Lost productivity for patient
Lost productivity for unpaid caregiver (e.g., family
member, neighbour, friend)
Lost productivity because of premature mortality
Intangible
costs
Pain and suffering
Fatigue
Anxiety
17. The Outcome Measurement
• Final health outcome considered as the effectiveness
measure
• If health outcome are multidimensional
– Result outcomes adjusted in a single index using health
utilities
– QALYs , Health year equivalent
18. Outcomes
• Clinical -Cure, comfort and survival
• Humanistic -Physical, emotional, social function, role
performance
• Economic -Expense, saving, cost avoidance
19. Types Of Pharmacoeconomic Studies
Based On Health Gain Outcome
• Four basic types
– Cost- Minimization Analysis (CMA)
– Cost –Effectiveness Analysis (CEA)
– Cost – Benefit Analysis (CBA)
– Cost – Utility Analysis (CUA)
20. Cost Minimization Analysis
• Simplest
• Outcomes - assumed to be equivalent
• Only costs of intervention compared
• Cannot be used when
– outcomes of intervention are expected to be different
21. TYPES OF PHARMACOECONOMIC STUDIES BASED ON HEALTH
GAIN OUTCOMES
METHODOLOGY COST
MEASUREMENT
UNIT
OUTCOME
MEASUREMENT
UNIT
Cost- Minimization
Analysis (CMA)
Rupees or
Monetary units
Assumed to be
equivalent in
comparable groups
COSTS(₹) OUTCOMES
22. Cost Effectiveness Analysis
• Outcome - natural units
• Outcomes easier to quantify
• Programs with different types of outcome can
not be compared
23. Cost Effectiveness Analysis
Two types
– Average cost-effectiveness ratio (ACER)
= Total health care costs (₹) ÷ clinical outcomes(not in ₹ )
– Incremental cost-effectiveness ratio (ICER )
= COST (A)- COST (B)(₹) ÷ Effectiveness A(%) -
Effectiveness B(%)
24. TYPES OF PHARMACOECONOMIC STUDIES BASED ON HEALTH
GAIN OUTCOMES
METHODOLOGY COST
MEASUREMENT
UNIT
OUTCOME
MEASUREMENT
UNIT
Cost –Effectiveness
Analysis (CEA)
Rupees or
Monetary units
Natural units (no of
life years gained ,
mm Hg B.P. ,
mMol /L of blood
sugar
COSTS(₹) OUTCOMES
25. Cost Utility Analysis
• Outcomes -years of life that are adjusted by “utility”
weights
• Range from 1.0 for “perfect health” to 0.0 for “dead”
• There are no consensus how to measure the utility
weights
• C:U Ratio = COST÷ QALY gained
26. TYPES OF PHARMACOECONOMIC STUDIES BASED ON HEALTH
GAIN OUTCOMES :
METHODOLOGY COST
MEASUREMENT
UNIT
OUTCOME
MEASUREMENT
UNIT
Cost – Utility
Analysis (CUA)
Rupees or
Monetary units
Quality adjusted life
years (QALYs) or
other utilities
COSTS(₹) OUTCOMES
27. Cost Benefit Analysis
• Both cost and benefits -monetary units
• Two major advantages
– advantages of implementation of treatment plan can be
determined
– Multiple programs can be compared
• Difficult to place monetary values on health
outcomes
28. TYPES OF PHARMACOECONOMIC STUDIES BASED ON HEALTH
GAIN OUTCOMES
METHODOLOGY COST
MEASUREMENT
UNIT
OUTCOME
MEASUREMENT
UNIT
Cost – Benefit
Analysis (CBA)
Rupees or
Monetary units
Rupees or
Monetary units
COSTS(₹) OUTCOMES
29. Other Types Of Analysis
• Cost Sequence Analysis
– Lists of costs and various outcomes presented
– No direct calculation or comparison between interventions
30. Other Types Of Analysis
• Cost Of Illness Analysis :
– Total economic burden (including prevention , treatment ,
losses caused by morbidity and mortality )
– May be direct costs or indirect costs
31. Importance Of Economic Evaluation
In setting up guidelines
Amending existing policies
Aiding clinical decision making
Resource allocation becomes more authentic
Develop effective, efficacious and available treatment to the
intended population.
To lessen health expenditures
32. Examples of pharmacoeconomic
studies
• To investigate the cost-effectiveness
– administering tranexamic acid (TXA) for the
treatment of significant haemorrhage following
trauma
• Early administration (within 3 hours) of TXA
would cost $ 66 (4837 ₹ )per LY saved in India
33. • Cost- Effectiveness of Preventing AIDS
Complications
• 3- month course of isoniazid plus rifampin and
a 6-month course of isoniazid
• Both decrease TB incidences in HIV patients
34. Conclusion
• Time and money can only be spent once- choice is
inevitable
• Pharmacoeconomics can enhance the quality of
practice by strengthening evaluation process and
increasing the probability that deliver better value in
patient care
36. Definition
The study of the use and effects of medication in
large number of people
The application of epidemiologic knowledge ,
methods and reasoning to the reasoning of the
effects (beneficial and adverse) and use of drugs
in human populations
38. Pharmacoepidemiological Research
• Pharmacoepidemiological studies focus on
– Global trends in prescribing
– Medication adherence
– Lifestyle effects on drug therapy
– Special population (Elderly, Pediatric, etc.) drug
therapy
– Drug Interactions
– Predictable ,uncommon and unpredictable ADRs
42. Summary
• Pharmacoeconomics provide the means to
quantify the value of pharmacotherapy
through balancing costs and outcomes
• Healthcare professionals will be prepared to
make better, more informed decisions
regarding the use of pharmaceutical products
and services.
43. TYPES OF PHARMACOECONOMIC STUDIES BASED ON HEALTH GAIN
OUTCOMES
METHODOLOGY COST
MEASUREMENT
UNIT
OUTCOME
MEASUREMENT UNIT
Cost- Minimization
Analysis (CMA)
Rupees or
Monetary units
Assumed to be equivalent
in comparable groups
Cost –Effectiveness
Analysis (CEA)
Rupees or
Monetary units
Natural units (no of life
years gained , mm Hg B.P. ,
mMol /L of blood sugar
Cost – Benefit
Analysis (CBA)
Rupees or
Monetary units
Rupees or Monetary units
Cost – Utility
Analysis (CUA)
Rupees or
Monetary units
Quality adjusted life years
(QALYs) or other utilities
44. Summary
• Information about drug safety and
effectiveness that is not available from pre-
marketing studies
• Pharmacoepidemiology is a field, bridging
between clinical pharmacology and
epidemiology
45. Summary
• From clinical pharmacology - focus of inquiry
• From epidemiology - methods of
inquiry
It compare the cost of various drugs with the outcomes, such as benefits of patients receiving the drugs and costs.
Over the last decade there has been tremendous interest in economic evaluations of healthcare programmes, especially in the pharmaceutical field.
Healthcare in developing countries including India is not solely driven by the best treatment option but by the easy availability and affordability for the patient .
The responsibility and the difficulty of the caregivers thereby increases as to maximize the beneficial outcomes and minimize the financial burden and increase humanistic outcome goals
Healthcare in developing countries including India is not solely driven by the best treatment option but by the easy availability and affordability for the patient .
The responsibility and the difficulty of the caregivers thereby increases as to maximize the beneficial outcomes and minimize the financial burden and increase humanistic outcome goals
The pharmacoeconomic evaluations can be classified according to the mode of data collection :
The economic value of a new medicine is calculated based on the comparator price and differential value . The comparator value is the price of the standard therapy /regimen prevailing in the present healthcare
Costs can be categorized broadly as Direct medical cost , Indirect medical cost , Indirect costs , Intangible costs
Calculation of these costs takes into consideration various expenditure made during the course of illness and loss of income due to abstinence from work or decrease of productivity.
Direct Costs : costs which are incurred for medical products or services used in prevention ,detection or treatment of the disease .
Direct Non Medical Costs : Non medical services that are results of illness , but do not involve purchasing medical services .
Indirect Non Medical Costs : costs of reduced productivity .
Intangible Costs : costs of pain, suffering, anxiety, or fatigue that occurs because of an illness or the treatment of an illness
Most of the economic evaluation guidelines,such as that of the ISPOR and the Dutch Health Care Insurance Board, are intended to be used for clinical studies and focus on measuring health(i.e. ,QALYs) as the main (or sometimes only)outcome measure of interest
Simplest to conduct
Outcomes are assumed to be equivalent
Only the costs of the intervention is compared
Cannot be used when outcomes of intervention are expected to be different
Outcomes easier to quantify as compared to CUA OR CBA
The average cost-effectiveness ratio (ACER) is the ratio of the cost to benefit of an intervention without reference to a comparator
The incremental cost-effectiveness ratio (ICER) is a statistic used in cost-effectiveness analysis to summarise the cost-effectiveness of a health care intervention. It is defined by the difference in cost between two possible interventions, divided by the difference in their effect
Measures the number of years of life gained by the treatment
Rough estimate
Both cost and benefits are valued in monetary units.
Measuring both cost and benefits in monetary units has two major advantages
Firstly the healthcare professionals can determine the effectiveness of the treatment and determine the advantages of implementation of that treatment plan
Multiple programs can be compared for their effectiveness irrespective of similar or different outcomes.
But it is difficult to place monetary values on health outcomes.
Direct Costs : costs which are incurred for medical products or services used in prevention ,detection or treatment of the disease .
Direct Non Medical Costs : Non medical services that are results of illness , but do not involve purchasing medical services .
Indirect Non Medical Costs : costs of reduced productivity .
Intangible Costs : costs of pain, suffering, anxiety, or fatigue that occurs because of an illness or the treatment of an illness
Direct Costs : costs which are incurred for medical products or services used in prevention ,detection or treatment of the disease .
Direct Non Medical Costs : Non medical services that are results of illness , but do not involve purchasing medical services .
Indirect Non Medical Costs : costs of reduced productivity .
Intangible Costs : costs of pain, suffering, anxiety, or fatigue that occurs because of an illness or the treatment of an illness
Direct Costs : costs which are incurred for medical products or services used in prevention ,detection or treatment of the disease .
Direct Non Medical Costs : Non medical services that are results of illness , but do not involve purchasing medical services .
Indirect Non Medical Costs : costs of reduced productivity .
Intangible Costs : costs of pain, suffering, anxiety, or fatigue that occurs because of an illness or the treatment of an illness
Direct Costs : costs which are incurred for medical products or services used in prevention ,detection or treatment of the disease .
Direct Non Medical Costs : Non medical services that are results of illness , but do not involve purchasing medical services .
Indirect Non Medical Costs : costs of reduced productivity .
Intangible Costs : costs of pain, suffering, anxiety, or fatigue that occurs because of an illness or the treatment of an illness
An economic analysis is a guide to better investment to obtain a better health value. Developing countries like India where government does not hold the responsibility for health insurance or any scheme covering expenditure of the health expenditure. Surveys indicate that Indians spend most of their income for fooding or secondly for purchasing medications. Inflation is beating the income hikes in an average earning individual’s life where health expenditure is on bargain.
an economic evaluation was carried out to investigate the cost-effectiveness of administering tranexamic acid (TXA) for the treatment of significant haemorrhage following trauma in India, Tanzania, and the United Kingdom. The LYs gained were estimated from a simple Markov model. The study showed that early administration of TXA to bleeding trauma patients is likely to be highly cost-effective in low, middle and high-income settings. Early administration (within 3 hours) of TXA would cost $ 66 per LY saved in India. However, it was important to demonstrate that it was likely to be cost-effective in countries with much more limited health care budgets, such as Tanzania and India where because of the high number of trauma victims this simple intervention can avert thousands of deaths every year
A study from South India used the Cost- Effectiveness of Preventing AIDS Complications International model, a computer-based, state transition model of HIV and TB combined with data of a clinical trial from the National Institute for Research in Tuberculosis. The analysis showed that a 3- month course of isoniazid plus rifampin and a 6-month course of isoniazid alone both decrease TB incidences in HIV patients. The therapy also came out to be cost –effective by WHO criteria